Semaglutide vs Tirzepatide: Which Produces More Weight Loss?

Published 12 July 2026  ·  8 min read

Two injectable weight-loss medications now dominate the conversation: semaglutide (sold as Wegovy for weight management, or Ozempic for type 2 diabetes) and tirzepatide (sold as Zepbound for weight management, or Mounjaro for type 2 diabetes). Both produce significant weight loss by historical standards. But which one works better — and does the answer actually change what you should do?

How They Differ at the Molecular Level

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone that slows gastric emptying, suppresses appetite, and regulates blood sugar. It acts on one type of receptor.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates both the GLP-1 receptor and the GIP receptor — glucose-dependent insulinotropic polypeptide. GIP is another gut hormone that plays a role in energy storage and appetite regulation. The combination of both pathways appears to produce a stronger and more sustained weight-loss effect than GLP-1 alone.

Put simply: semaglutide pulls one lever. Tirzepatide pulls two. The clinical data suggests this matters.

The Trial Data

The two key programmes are STEP (for semaglutide) and SURMOUNT (for tirzepatide). Comparing across programmes is imperfect because the trials enrolled different populations and ran at different times. The SURMOUNT-5 trial, which compared them directly, gives the clearest picture.

SURMOUNT-5 enrolled adults with obesity or overweight without type 2 diabetes — the same core population as STEP 1 — and ran for 72 weeks. Tirzepatide produced approximately 47% more relative weight loss than semaglutide. This is a meaningful difference and the first randomised, controlled head-to-head comparison between these two drugs.

What the Numbers Mean in Practice

If you start at 100kg: semaglutide averages 13.7kg lost. Tirzepatide averages 20.2kg lost. At 120kg: 16.4kg versus 24.2kg. These are real differences in outcomes that would be clinically meaningful to most people.

But averages obscure the full story. In SURMOUNT-5, some participants on semaglutide lost more weight than the average tirzepatide participant. Some participants on tirzepatide didn't respond strongly. Individual variation is substantial on both drugs.

The question isn't just which drug is stronger on average — it's which drug is right for a given individual, considering access, cost, tolerability and personal response.

Side Effect Comparison

Both semaglutide and tirzepatide have similar side effect profiles: nausea, vomiting, constipation and diarrhoea are the most common with both. The frequency and severity differ modestly between the two molecules, and individual tolerance varies.

In general, tirzepatide's side effect profile is considered at least comparable to semaglutide, though some studies have noted slightly different patterns — for example, somewhat less nausea at equivalent efficacy levels. But this isn't a consistent finding across all data and shouldn't be the primary basis for choosing between them.

Access and Cost

In many markets, access and insurance coverage is a bigger practical determinant of which medication you'll use than the trial data. Semaglutide has been on the market longer and has broader formulary coverage in more countries. Tirzepatide is newer and coverage is still expanding. In some markets, one is simply not available or not affordable.

Monthly costs without insurance coverage are significant for both — often several hundred dollars or more depending on geography. Some people access compounded versions (where legally available) during periods of brand shortage, which carries its own considerations.

Which Should You Ask Your Prescriber About?

If you have type 2 diabetes, your prescriber will likely factor in that condition's management when choosing between options. Both classes have cardiovascular and metabolic benefits beyond weight loss, but the evidence base and specific indications differ.

If your primary goal is maximum weight loss and both are accessible and affordable in your situation, tirzepatide currently has the stronger average efficacy data. But the "better drug on average" is only meaningful if you can access it, afford it, tolerate it and actually stay on it. The best GLP-1 medication is the one you can consistently take.

What Comes Next

Pharmaceutical development in this space is moving quickly. Oral semaglutide for weight management is in late-stage development. Next-generation triple agonists (targeting GLP-1, GIP and glucagon receptors simultaneously) are in clinical trials. The SURMOUNT-5 data that currently favours tirzepatide may itself be superseded by even more effective drugs over the coming few years.

For now: both semaglutide and tirzepatide are genuinely effective weight-loss medications by any historical standard. Tirzepatide produces higher average weight loss in head-to-head comparisons. Whether that average difference translates to better outcomes for you specifically is a question your prescriber is best placed to help you answer.

Medical disclaimer: This article discusses clinical trial data as published at the time of writing. The comparison of semaglutide and tirzepatide is based on aggregate trial results, which do not predict individual outcomes. Medical decisions should always be made with a qualified healthcare professional who knows your personal circumstances.